Axsome Therapeutics Inc

NASDAQ:AXSM  
58.38
-1.65 (-2.75%)
Regulatory, Earnings Announcements

Axsome Therapeutics Announces Rapid And Substantial Improvement In Depressive Symptoms Achieved By 44% Of Patients At 2 Weeks, 67% At 6 Weeks

Published: 12/02/2020 11:51 GMT
Axsome Therapeutics Inc (AXSM) - Axsome Therapeutics Announces Positive Results From the Comet-trd Trial of Axs-05 in Patients With Treatment Resistant Depression.
Axsome Therapeutics Inc - Rapid and Substantial Improvement in Depressive Symptoms Achieved by 44% of Patients at 2 Weeks, 67% at 6 Weeks.
Axsome Therapeutics Inc - Rapid and Substantial Improvement in Functioning Achieved by 53% of Patients at 2 Weeks, 64% of Patients at 6 Weeks.
Axsome Therapeutics Inc - Marked Or Moderate Improvement in Depression Achieved by 49% of Patients at 2 Weeks, 78% of Patients at 6 Weeks.
Axsome Therapeutics Inc - Axs-05 Was Well Tolerated in Comet Trial.
Axsome Therapeutics Inc - Safety Profile Observed Was Consistent With What Was Previously Reported in Controlled Trials of Axs-05 in Mdd.
Axsome Therapeutics - Results of Phase 2 Comet-si Trial of Major Depressive Disorder Patients With Suicidal Ideation Are Still Expected Before Year End.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.92

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.10

More details on our Analysts Page.